Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 9 institutions in 2 countries.
Caitlin W ElgartenDepartment of Pediatrics Division of Oncology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA.ORCID https://orcid.org/0000-0002-2474-3031
John A KairallaDepartment of Biostatistics University of Florida Gainesville Florida USA.
Joel C ThompsonDepartment of Pediatrics Division of Hematology/Oncology/Bone Marrow Transplant Children's Mercy Hospital University of Missouri - Kansas City Kansas City Missouri USA.ORCID https://orcid.org/0000-0002-9609-7606
Cindy WangDepartment of Biostatistics University of Florida Gainesville Florida USA.
Susan ConwayDepartment of Biostatistics University of Florida Gainesville Florida USA.
Mignon L LohBen Towne Center for Childhood Cancer Research Seattle Children's Research Institute and Department of Pediatrics Seattle Children's Hospital University of Washington Seattle Washington USA.
Elizabeth A RaetzLaura and Isaac Perlmutter Cancer Center at NYU Langone New York New York USA.
Rachel E RauPediatric Hematology/Oncology Baylor College of Medicine Houston Texas USA.
Anne AngiolilloCenter for Cancer and Blood Disorders Children's National Medical Center Washington District of Columbia USA.
Karen R RabinPediatric Hematology/Oncology Baylor College of Medicine Houston Texas USA.
Sarah AlexanderDivision of Hematology/Oncology Hospital for Sick Children Toronto Ontario Canada.
University of Florida · USBaylor College of Medicine · USHospital for Sick Children · CAChildren's Healthcare of Atlanta · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USChildren's National · USNYU Langone Health · USSeattle Children's Hospital · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
Understanding longitudinal microbiome change in relation to immunologic outcomes in pediatric SCT recipients.K23HL161309 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Caitlin Walfoort Elgarten · 2022 to 2026
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731. · full record | OpenQuestion